

REMARKS

Upon entry of the Amendment, claims 1-4 and 6-16 will be all the claims pending in the application. Claim 1 has been amended. Claim 5 has been canceled without prejudice. Claims 10-16 have been withdrawn from consideration.

In the present Amendment, claim 1 has been amended to incorporate the subject matter previously recited in claim 5.

No new matter has been added, and entry of the Amendment is respectfully requested.

I. Claim Rejection under 35 U.S.C. § 102(b)

Claims 1-4, 9 are rejected under 35 U.S.C. § 102(b) as being anticipated by United States Patent No. 5,929,194 to Woo et al. ("Woo").

Applicants respectfully traverse.

Claim 1 has been amended to incorporate the subject matter previously recited in claim 5. Claim 5 was not included in anticipation rejection based on Woo. Woo does not anticipate the present claims because Woo does not disclose or suggest each and every element of the claimed subject matter, as presently recited in claim 1.


Accordingly, Applicants respectfully request reconsideration and withdrawal of the foregoing §102 rejection of present claims.

II. Claim Rejection under 35 U.S.C. § 103

Claim 1-9 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Woo.

Applicants submit that this rejection should be withdrawn because Woo does not disclose or render obvious the presently claimed arylamine compound.

Claim 1 presently recites an arylamine compound of the formula:




wherein, Ar independently each occurrence is a group comprising one or more divalent aromatic groups, and optionally two Ar groups separated by a single NX group may be joined together by a second covalent bond or by a bridging group, thereby forming a fused multiple ring system; X is an inert substituent or a cross-linkable group, with the proviso that in at least one occurrence in said compound; X is a crosslinkable group; Z independently each occurrence is

halo, cyano, triflate azide, $-B(OR^1)_2$, or $-B \begin{array}{c} O \\ \diagup \quad \diagdown \\ O \end{array} R^2$, wherein R^1 , independently in each occurrence, is hydrogen or a C_{1-10} alkyl group, and R^2 , independently each occurrence, is a C_{2-10} alkylene group, n is 1 or 2; and n' is 0, 1 or 2.


The Examiner seems to take the position that Woo discloses arylamine compounds containing cyclobutene group that would render the elected species di(4-bromophenyl)benzocyclobutane amine obvious.

In this regard, the Examiner first points to Example 11 of Woo as teaching the following compound (having di(4-bromophenyl) structure). *See* page 9 of the Action.




(Example 11 of Woo)

Then, the Examiner points to Examples 5 and 21 of Woo as teaching arylamine compounds containing cyclobutene group. *See* page 11 of the Action.



(Example 5 of Woo)



(Example 21 of Woo)

The Examiner is supporting his rejection that one of ordinary skill would substitute the cyclobutene containing aromatic ring of Examples 5 and 21 of Woo for the toluene ring of Example 11 of Woo.

Applicants respectfully disagree. Aside from improper hindsight, there is no reason or motivation to select and modify the reference compound of Example 11 of Woo in the manner suggested by the Examiner with reasonable expectation of success.

Accordingly, it is respectfully submitted that the present claims are patentable over Woo. Applicants respectfully request reconsideration and withdrawal of the present §102 and §103 rejections based on Woo.

II. Double Patenting Rejection

Claim 1-2, 6 and 9 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 and 4 of co-pending Application No. 10/579,215 ("the '215 application").

Applicants respectfully traverse.

Claim 1 has been amended to incorporate the subject matter previously recited in claim 5. Claim 5 was not included in the provisional nonstatutory obviousness-type double patenting

rejection based on co-pending Application No. 10/579,215 ("the '215 application"). For at least this reason alone, the presently claimed arylamine compound is patentably distinct from what is claimed in '215 Application.

Further, in claim 1 of the present application, X is defined as a crosslinkable group.

The Examiner considers that in '215 Application, for example, tolyl (R'=methyl in claim 4) of '215 Application can polymerize through free radical, and therefore corresponds to the cross-linkable group of the present claim 1.

The Examiner is not correct.

As disclosed in the present specification, at page 6, lines 10-11, the preferred non-crosslikable X groups include C₁₋₁₀ alkylphenyl. Tolyl is an alkylphenyl which is non-crosslinkable.

Accordingly, the present compound having a crosslinkable group is patentably distinct from the monomer of '215 Application which does not have a crosslinkable group.

In view of the above, withdrawal of the present provisional double patenting rejection based on co-pending Application No. 10/579,215 is respectfully requested.

III. Conclusion

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

/Yan Lan/

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Yan Lan
Registration No. 50,214

Date: March 8, 2010